BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone® RTSM (randomization and trial supply management) service. The app is designed to enhance clinical trial supply management processes, increase patient safety, and improve the chain of custody record for clinical supplies.
Using built-in barcode scanning capabilities, clinical trial site staff, including principal investigators (PIs), study nurses, and clinical research associates (CRAs), can utilize the app to streamline common clinical trial responsibilities. Tasks including confirming correct treatment allocation, dispensing to patients, and processing of medicinal product returns can now be managed more efficiently, reducing time and human errors.
“Clinical trials management is often hampered by administrative supply-related tasks at site locations. Simplifying systems and processes and removing manual data entry can save staff time and increase patient safety,” said Ken Faulkner, Corporate Vice President, PAREXEL Informatics. “Our mobile app is the latest extension of the ClinPhone RTSM service, further demonstrating our commitment to simplifying the drug development journey through the innovative application of social, mobile, analytic, and cloud technologies.”
PAREXEL’s ClinPhone RTSM service has been deployed on over 3,700 studies and more than 2.5 million patients, with the largest of those studies randomizing and supplying more than 60,000 patients. The ClinPhone RTSM mobile app is available worldwide for use on Android and iOS platforms. For more details, please visit: https://www.parexel.com/solutions/informatics/randomization-and-trial-supply-management/rtsm-mobile-app.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the first quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.